Application will provide additional protection for intellectual property already filed with the USPTO
Vancouver, British Columbia, June 22, 2022 /PRNewswire/- Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental healthcare company dedicated to innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience”) has File a patent application to the World Intellectual Property Organization (WIPO), an agency of the United Nations, for rapid production processes psilocybin and other fungal species that contain psilocybin and other compounds.
A provisional patent application for the method was filed in June 24, 2021. With this additional application, international patent protection will be extended to all WIPO member states that have signed the Patent Cooperation Treaty (PCT), including Australia, Germany, Netherlands and U.K.where psychedelic research is currently active.
“WIPO is an important global forum that provides assurance to the patent offices of member states. Numinus believes that strong evidence supporting the production process will further inform regulators as they consider policy changes to enable psychedelic-assisted therapies and products more accessible,” said Sharan Sidhu, Vice President of Scientific Research, Innovation and Laboratory Operations at Numinus. “We look forward to advancing current research to pave the way for eventual commercialization and mainstream access.”
The purpose of this process is to significantly increase the yield of therapeutic agents for adjunctive psychedelic therapy, while reducing product variability, increasing production efficiency and ultimately reducing commercialization costs. Since the first submission, datasets validating other fungal assignment processes have been completed, extending their potential applications and scope from psilocybin to other active compounds.
“The app is part of Numinus’ long-term IP strategic focus on scalable and sustainable production that drives the research, development and delivery of innovative psychedelic-derived formulations North America and beyond,” said Peyton NyquivistFounder and CEO of Numinus.
Numinus Wellness helps people recover and stay healthy by developing and delivering innovative mental health services and access to safe, evidence-based psychedelic-assisted therapy. The Numinus model – which includes psychedelic production, research and clinical care – is at the forefront of a transformation aimed at curing rather than managing symptoms of depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapy into mainstream clinical practice and laying the foundations for a healthier society.
Neither Numinus Wellness Inc. nor any of its subsidiaries is a licensed health services professional firm. Numinus and its subsidiaries provide managed services to affiliated professional companies that provide medical care to patients in jurisdictions where only companies with a valid license can provide medical care. Numinus and its subsidiaries provide medical care directly to patients in authorized jurisdictions.
Statements and other information contained in this press release regarding expected future events constitute forward-looking statements. Forward-looking statements are usually, but not always, identified by the use of words such as “seek,” “anticipate,” “believe,” “plan,” “estimate,” “anticipate,” and “intend,” and events “may,” “will,” “, “should”, “may” or “may” or other similar expressions. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements. Forward-looking statements are based on management’s estimates and opinions as of the date they are made. The company undertakes no obligation to update forward-looking statements, even if circumstances or management’s estimates or opinions should change, except as required by applicable law. Investors should not place undue reliance on forward-looking statements.
Source Numinus Wellness Inc.